Literature DB >> 27031211

Synthesis, characterization and biological evaluation of benzothiazoles and tetrahydrobenzothiazoles bearing urea or thiourea moieties as vasorelaxants and inhibitors of the insulin releasing process.

Kamel Harrouche1, Jean-Francois Renard2, Nafila Bouider1, Pascal de Tullio2, Eric Goffin2, Philippe Lebrun3, Gilles Faury4, Bernard Pirotte5, Smail Khelili1.   

Abstract

A series of 1,3-benzothiazoles (series I) and 4,5,6,7-tetrahydro-1,3-benzothiazoles (series II) bearing an urea or a thiourea moiety at the 2-position were synthesized and tested as myorelaxants and inhibitors of insulin secretion. Several compounds (i.e. 13u and 13v) from series I showed a marked myorelaxant activity. Benzothiazoles bearing a strong electron withdrawing group (NO2, CN) at the 6-position and an alkyl group linked to the urea or the thiourea function at the 2-position were found to be the most potent compounds. The weak vasorelaxant activity of series II compounds evidenced the necessity of the presence of a complete aromatic heterocyclic system. The myorelaxant activity of some active compounds was reduced when measured on aorta rings precontracted by 80 mM KCl or by 30 mM KCl in the presence of 10 μM glibenclamide, suggesting the involvement of KATP channels in the vasorelaxant effect. Some compounds of series I tested on rat pancreatic islets provoked a marked inhibition of insulin secretion, among which 13a exhibited a clear tissue selectivity for pancreatic β-cells.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Benzothiadiazine; Benzothiazole; Diazoxide; K(ATP) channel; Pinacidil; Potassium channel openers

Mesh:

Substances:

Year:  2016        PMID: 27031211     DOI: 10.1016/j.ejmech.2016.03.028

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  1 in total

1.  Synthesis of biologically active derivatives of 2-aminobenzothiazole.

Authors:  Larisa V Zhilitskaya; Nina О Yarosh
Journal:  Chem Heterocycl Compd (N Y)       Date:  2021-05-12       Impact factor: 1.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.